Nothing Special   »   [go: up one dir, main page]

EA200601575A1 - Казеиновые пептиды и их терапевтическое применение - Google Patents

Казеиновые пептиды и их терапевтическое применение

Info

Publication number
EA200601575A1
EA200601575A1 EA200601575A EA200601575A EA200601575A1 EA 200601575 A1 EA200601575 A1 EA 200601575A1 EA 200601575 A EA200601575 A EA 200601575A EA 200601575 A EA200601575 A EA 200601575A EA 200601575 A1 EA200601575 A1 EA 200601575A1
Authority
EA
Eurasian Patent Office
Prior art keywords
peptides
casein
stimulation
therapeutic application
casein peptides
Prior art date
Application number
EA200601575A
Other languages
English (en)
Inventor
Цви Сидельман
Original Assignee
Пептера Фармасьютикалс Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пептера Фармасьютикалс Лтд. filed Critical Пептера Фармасьютикалс Лтд.
Publication of EA200601575A1 publication Critical patent/EA200601575A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4732—Casein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Биологически активные пептиды, которые являются производными альфаS1-, альфаS2-, бета- или капа-казеиновых фракций казеина молока или сходны с их последовательностями. Эти пептиды способны модулировать иммунитет и обладают другими терапевтическими действиями, включая, без ограничений, стимуляцию и усиление иммунного ответа, защиту от вирусной инфекции, нормализацию уровней холестерина в сыворотке крови и стимуляцию гемопоэза. Данные казеиновые пептиды нетоксичны и могут применяться для лечения и предупреждения иммунных патологий, диабета, гиперхолестеринемии, гематологических расстройств и заболеваний, связанных с вирусными инфекциями.
EA200601575A 2004-03-01 2005-02-20 Казеиновые пептиды и их терапевтическое применение EA200601575A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54840104P 2004-03-01 2004-03-01
PCT/IL2005/000211 WO2005081628A2 (en) 2004-03-01 2005-02-20 Casein derived peptides and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
EA200601575A1 true EA200601575A1 (ru) 2007-06-29

Family

ID=34910999

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200601575A EA200601575A1 (ru) 2004-03-01 2005-02-20 Казеиновые пептиды и их терапевтическое применение

Country Status (13)

Country Link
US (1) US20070203060A1 (ru)
EP (1) EP1751179A4 (ru)
JP (1) JP2008509073A (ru)
KR (1) KR20070007128A (ru)
CN (1) CN101124261A (ru)
AU (1) AU2005215943A1 (ru)
BR (1) BRPI0507822A (ru)
CA (1) CA2558155A1 (ru)
EA (1) EA200601575A1 (ru)
MX (1) MXPA06010014A (ru)
NO (1) NO20064388L (ru)
WO (1) WO2005081628A2 (ru)
ZA (1) ZA200607735B (ru)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4654418B2 (ja) * 2004-03-31 2011-03-23 独立行政法人産業技術総合研究所 上皮系細胞増殖促進剤
JP5068174B2 (ja) * 2004-12-23 2012-11-07 カンピナ ネーデルランド ホールディング ビー．ブイ． Ｄｐｐ−ｉｖを阻害するペプチド中に濃縮されたタンパク質の加水分解物及びその使用
EA016396B1 (ru) * 2005-02-24 2012-04-30 ДСМ АйПи АССЕТС Б.В. Способ получения пептидного гидролизата, содержащего ipp, и применение указанного гидролизата для производства функционального пищевого продукта, предназначенного для поддержания здоровья сердечно-сосудистой системы
EA016039B1 (ru) 2005-05-02 2012-01-30 Милеутис Лтд. Способы ухода за лактирующими животными и фармацевтические композиции, используемые для их осуществления
SI2236608T1 (sl) 2005-10-04 2017-03-31 Soligenix, Inc. Novi peptidi za zdravljenje in preprečevanje motenj, povezanih z imunskim sistemom, vključno zdravljenje in preprečevanje infekcije z moduliranjem prirojene imunosti
US20090214498A1 (en) * 2005-11-21 2009-08-27 Teagasc- National Diary Products Research Centre Antimicrobial peptides and bacterial strains that produce them
JP2009517464A (ja) 2005-11-30 2009-04-30 カンピーナ ネーダーランド ホールディング ビー．ブイ． グルカゴン様ペプチド１の活性を増強するタンパク質加水分解物の使用
US7989160B2 (en) 2006-02-13 2011-08-02 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in the process of bone remodeling
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
JP2007254449A (ja) * 2006-02-22 2007-10-04 Snow Brand Milk Prod Co Ltd 脂質改善剤
JP5177778B2 (ja) * 2006-02-24 2013-04-10 雪印メグミルク株式会社 ペプチド
GB2436328A (en) * 2006-03-22 2007-09-26 Regen Therapeutics Plc Peptide derived from colostrinin
EP2007413A4 (en) * 2006-04-11 2010-07-14 Mileutis Ltd MAINTENANCE FOR IMPROVED REPRODUCTION EFFICIENCY
NZ594814A (en) * 2006-04-28 2013-03-28 Megmilk Snow Brand Co Ltd Peptide that is derived from a milk protein and has an antioxidative effect and also acts as a blood adiponectin level increase promotion and/or decrease inhibition agent
EP3231442B1 (en) 2006-06-23 2019-12-25 ADC Therapeutics SA Polynucleotides and polypeptide sequences involved in cancer
JP5188731B2 (ja) * 2007-03-02 2013-04-24 雪印メグミルク株式会社 ペプチド
US20110190215A1 (en) * 2008-05-15 2011-08-04 Regen Therapeutics Plc Therapeutic use of peptides
NZ571856A (en) * 2008-10-09 2011-02-25 Fonterra Corporate Res And Dev Ltd Use of a phospholipid and ganglioside composition for the treatment or prevention of gout
CA3050455A1 (en) 2008-11-03 2010-06-03 Adc Therapeutics Sa Antibodies that specifically block the biological activity of a tumor antigen
CA2748449A1 (en) 2008-12-27 2010-07-15 Pawan Saharan Mammalian colostrum derived nanopeptides for broadspectrum viral and recurrent infections with a method of isolation thereof
EP2413952B2 (en) 2009-04-03 2019-10-02 Société des Produits Nestlé S.A. Improvement in promotion of healthy catch-up growth
WO2010144968A1 (en) * 2009-06-19 2010-12-23 Oral Health Australia Pty Ltd Casein derived protease inhibitory peptides
CA2779161A1 (en) * 2009-10-28 2011-05-05 University Of Manitoba Yellow pea seed protein-derived peptides
JP5479884B2 (ja) * 2009-12-28 2014-04-23 カルピス株式会社 脳機能改善用組成物および脳機能を改善する方法
CA2797658C (en) 2010-04-21 2021-06-08 Mileutis Ltd. Casein peptide for use in the treatment of uterine infections
PT105073A (pt) * 2010-04-26 2011-10-26 Consejo Superior Investigacion Processo de obtenção de extractos peptídicos bioactivos através da hidrólise de proteínas de soro de leite com enzimas de cynara cardunculus, referidos extractos e respectivas utilizações
CN103492418B (zh) 2011-03-31 2016-06-29 阿莱斯亚生物疗法股份有限公司 针对肾相关抗原1的抗体及其抗原结合片段
US8865155B2 (en) * 2011-09-29 2014-10-21 Centro De Investigacion En Alimentacion Y Desarrollo, A.C. (Ciad) Lactococcus lactis strains, and bacterial preparations thereof, for the production of bioactive peptides having anti-hypertensive and cholesterol-lowering effects in mammals; nutritional and therapeutic products produced therefrom
EA034414B1 (ru) 2012-01-09 2020-02-05 Адс Терапьютикс Са Способ лечения тройного негативного рака молочной железы
JP5976004B2 (ja) * 2012-03-09 2016-08-23 森永乳業株式会社 ジペプチジルペプチダーゼ−ｉｖ阻害剤
CN104507969A (zh) 2012-07-19 2015-04-08 阿莱斯亚生物疗法股份有限公司 抗siglec-15抗体
CN102964427B (zh) * 2012-12-12 2014-01-15 上海交通大学 一种生物活性多肽qepvl及其制备和应用
CN103012552B (zh) * 2012-12-12 2014-03-12 上海交通大学 一种生物活性多肽qepv及其制备和应用
US9138455B2 (en) 2013-03-15 2015-09-22 Mead Johnson Nutrition Company Activating adiponectin by casein hydrolysate
US9352020B2 (en) 2013-03-15 2016-05-31 Mead Johnson Nutrition Company Reducing proinflammatory response
US10251928B2 (en) * 2014-11-06 2019-04-09 Mead Johnson Nutrition Company Nutritional supplements containing a peptide component and uses thereof
US8889633B2 (en) * 2013-03-15 2014-11-18 Mead Johnson Nutrition Company Nutritional compositions containing a peptide component with anti-inflammatory properties and uses thereof
US9345727B2 (en) 2013-03-15 2016-05-24 Mead Johnson Nutrition Company Nutritional compositions containing a peptide component and uses thereof
US9345741B2 (en) 2013-03-15 2016-05-24 Mead Johnson Nutrition Company Nutritional composition containing a peptide component with adiponectin simulating properties and uses thereof
US9289461B2 (en) 2013-03-15 2016-03-22 Mead Johnson Nutrition Company Reducing the risk of autoimmune disease
ES2899191T3 (es) * 2014-04-03 2022-03-10 AllerGenis LLC Péptidos y procedimientos de detección de alergia alimentaria
CN104697830B (zh) * 2015-02-10 2018-06-15 深圳市新产业生物医学工程股份有限公司 用于hiv检测的酸性处理剂、样本预处理方法、试剂盒及检测方法
WO2016208641A1 (ja) * 2015-06-22 2016-12-29 株式会社明治 血中ヘモグロビン増加用組成物
JP7157043B2 (ja) * 2017-03-03 2022-10-19 森永乳業株式会社 Ｇｌｐ－１分泌促進剤及び組成物
CN107188949B (zh) * 2017-07-06 2019-12-24 浙江辉肽生命健康科技有限公司 一种生物活性多肽eintvqvtst及其制备方法和应用
CN107176995B (zh) * 2017-07-06 2019-12-24 浙江辉肽生命健康科技有限公司 一种生物活性多肽skvlpvpekavpypq及其制备方法和应用
JP7122018B2 (ja) * 2017-09-15 2022-08-19 カイン サイエンス シーオー．，エルティーディー． 自己免疫疾患および骨疾患の治療剤としてのペプチドの用途
CN107903314A (zh) * 2017-11-14 2018-04-13 上海交通大学 一种生物活性多肽eviesppeintv及其制备方法和应用
TWI655203B (zh) * 2017-11-16 2019-04-01 國立中興大學 新穎胜肽、含有該胜肽之組合物及其用途
CN107814835B (zh) * 2017-12-01 2020-04-28 熊猫乳品集团股份有限公司 一种生物活性多肽avpitptlnreq及其制备方法和应用
CN107827971B (zh) * 2017-12-07 2020-04-14 浙江辉肽生命健康科技有限公司 一种生物活性多肽qsltltdve及其制备方法和应用
CN107814839A (zh) * 2017-12-07 2018-03-20 浙江辉肽生命健康科技有限公司 一种生物活性多肽pigsensekttmpl及其制备方法和应用
CN107759682B (zh) * 2017-12-07 2021-03-02 浙江辉肽生命健康科技有限公司 一种生物活性多肽pigsensgkttmpl及其制备方法和应用
CN107880102A (zh) * 2017-12-07 2018-04-06 浙江辉肽生命健康科技有限公司 一种生物活性多肽peviesppein及其制备方法和应用
CN107880105B (zh) * 2017-12-11 2020-06-16 浙江辉肽生命健康科技有限公司 一种生物活性多肽vpitptlnr及其制备方法和应用
CN108017703B (zh) * 2017-12-11 2020-07-17 浙江辉肽生命健康科技有限公司 一种生物活性多肽vpitptln及其制备方法和应用
CN107880106B (zh) * 2017-12-11 2020-06-16 浙江辉肽生命健康科技有限公司 一种生物活性多肽vpitptlnre及其制备方法和应用
CN107880104A (zh) * 2017-12-11 2018-04-06 浙江辉肽生命健康科技有限公司 一种生物活性多肽sppeintvqvt及其制备方法和应用
CN107827972A (zh) * 2017-12-11 2018-03-23 浙江辉肽生命健康科技有限公司 一种生物活性多肽speviesppein及其制备方法和应用
CN108017709B (zh) * 2017-12-12 2020-04-10 浙江辉肽生命健康科技有限公司 一种生物活性多肽kepmigvnqela及其制备方法和应用
CN107814840B (zh) * 2017-12-12 2020-04-10 浙江辉肽生命健康科技有限公司 一种生物活性多肽pkypvepf及其制备方法和应用
CN108034002A (zh) * 2017-12-12 2018-05-15 浙江辉肽生命健康科技有限公司 一种生物活性多肽peviesppeintv及其制备方法和应用
CN108017708A (zh) * 2017-12-12 2018-05-11 浙江辉肽生命健康科技有限公司 一种生物活性多肽npigsensekttmpl及其制备方法和应用
CN107880108A (zh) * 2017-12-12 2018-04-06 浙江辉肽生命健康科技有限公司 一种生物活性多肽sfsdipnpigse及其制备方法和应用
KR102073824B1 (ko) * 2018-04-11 2020-02-05 강원대학교산학협력단 간 보호용 건강기능식품 및 이의 제조 방법
WO2023272386A1 (en) * 2021-06-29 2023-01-05 Gill Thomas A Peptides for regulating glucose
CN113952446B (zh) * 2021-09-03 2023-12-05 河南省医药科学研究院 生物活性肽在抑制骨髓毒性中的应用
CN115724982B (zh) * 2022-08-12 2023-07-04 广西壮族自治区水牛研究所 一种用于检测水牛奶中掺假普通牛乳的单克隆抗体及其制备方法和用途
NL2033588B1 (en) * 2022-11-22 2024-05-30 Univ Ningbo Duck liver protein-derived anti-inflammatory and antimicrobial functional peptide and preparation method and application thereof
CN117567586A (zh) * 2023-10-25 2024-02-20 广州菲勒生物科技有限公司 一种富含唾液酸化肽的水解酪蛋白的制备方法及其在调节肠道菌群中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968901A (en) * 1989-10-30 1999-10-19 Andersson; Bengt Antibacterial composition
US5707968A (en) * 1994-05-26 1998-01-13 Abbott Laboratories Inhibition of attachment of H.influenzae to human cells
IL134830A0 (en) * 2000-03-01 2001-05-20 Chay 13 Medical Res Group N V Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them
TWI268138B (en) * 2000-05-11 2006-12-11 Kanebo Seiyaku Ltd Composition containing peptide and electrolyte excretion enhancing substance, and food containing the same
EP1556074A4 (en) * 2001-08-30 2008-05-07 Chay 13 Medical Res Group N V CASEIN DERIVED PEPTIDES AND THEIR USE IN THERAPY

Also Published As

Publication number Publication date
US20070203060A1 (en) 2007-08-30
WO2005081628A3 (en) 2007-10-18
AU2005215943A1 (en) 2005-09-09
EP1751179A4 (en) 2009-03-25
CA2558155A1 (en) 2005-09-09
JP2008509073A (ja) 2008-03-27
CN101124261A (zh) 2008-02-13
WO2005081628A2 (en) 2005-09-09
BRPI0507822A (pt) 2007-07-10
KR20070007128A (ko) 2007-01-12
MXPA06010014A (es) 2007-03-07
NO20064388L (no) 2006-11-28
EP1751179A2 (en) 2007-02-14
ZA200607735B (en) 2008-05-28

Similar Documents

Publication Publication Date Title
EA200601575A1 (ru) Казеиновые пептиды и их терапевтическое применение
NO20024157D0 (no) Kasein-avledete peptider og anvendelser derav i terapi
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
ATE475423T1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen
CY1116464T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
EA200801570A1 (ru) Стабильные белковые препараты
BRPI0518793A2 (pt) mÉtodos para tratar, controlar ou prevenir uma doenÇa ou distérbio de imunodeficiÊncia, e para melhorar a resposta imune a um imunogene, e, composiÇço farmacÊutica
EA200000911A1 (ru) Новые кристаллические формы антивирусного соединения бензимидазола
BRPI0813699A2 (pt) Formulações de proteína de fusão glp-1-fc
UA99094C2 (ru) Способ лечения пациента с системной красной волчанкой
MX2021008207A (es) Proteínas de fusión multifuncionales y usos de las mismas.
BRPI0510659A (pt) indução de uma resposta imunológica contra polissacarìdeos de streptococcus pneumoniae
ATE516366T1 (de) Regulierte aptamer-therapeutika
WO2021207213A3 (en) Methods to prevent sars-cov-2 infection and treat covid-19
ES2340842T3 (es) Anticuerpos anti-apc no neutralizantes.
WO2004026260A3 (en) Prophylactic and therapeutic hiv aptamers
KR20040078639A (ko) 카세인 유도 펩타이드 및 이들의 치료 용도
WO2006025995A3 (en) Compositions and methods using md-2 mutants and chimeric proteins
EA200600314A1 (ru) Использование растворимого cd164 при воспалительных и/или аутоимунных нарушениях
ATE544453T1 (de) Kombinationstherapien mit l-fmau zur behandlung von hepatitis-b-virus-infektionen
FR3085679B1 (fr) Composes analogues de la squalamine et leur utilisation medicale
WO2020112847A3 (en) Immune supplement composition
BRPI0516832A (pt) uso para alfa-simpatomiméticos com uma estrutura de 2-imidazolina
DE60116466D1 (de) Myeloider koloniestimulierungsfaktor und verwendungen davon
DE69803052D1 (de) Therapeutischer viraler wirkstoff, welcher das fortschreiten von tumoren stoppt